ARTICLE | Management Tracks
In wake of Anthos buyout, CFO McIntyre joins Inhibikase
BioCentury’s Management Roundup also includes updates from Galapagos, Proqr, GC, Gates MRI, Viatris and AB Sciex
April 16, 2025 1:06 AM UTC
Inhibikase Therapeutics Inc. (NASDAQ:IKT) hired David McIntyre as CFO, following last week’s resignation of Garth Lees-Rolfe from the role. A former partner at Apple Tree Partners, McIntyre was most recently CFO of Anthos Therapeutics Inc., which Novartis AG (SIX:NOVN; NYSE:NVS) acquired in a February 2025 deal.
CFO and COO Thad Huston will leave Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and return to the U.S., effective Aug. 1. The company said Huston made his decision for personal and professional reasons; he had joined in 2023 as the company turned its focus to cell therapies...